# Kevin Xu

> Kevin Xu is the Chairman and CEO of ClinChoice, a global full-service contract research organization (CRO) with more than 30 years of history, roughly 4,000 staff, and operations across 15+ countries. He arrived in the corner office from the investor's side of the table: for over 15 years he was a Managing Director at Goldman Sachs, where he built and ran the firm's Asia-Pacific Healthcare and Life Sciences investing practice, leading deals across biotech, pharma, medtech, CROs/CDMOs and digital health. Trained in neuroscience and clinical psychology before finance, he is an outspoken advocate for destigmatizing mental illness and an unlikely wake-surfer.

- **Role:** Chairman & CEO at ClinChoice
- **Organizations:** ClinChoice, Goldman Sachs (former), Zhenge Biotech (board), Puyi Biotechnology (board)
- **Education:** B.S., University of Maryland, MSc, Neuroscience and Clinical Psychology, King's College London, Master of Finance, University of Cambridge
- **Known for:** Over 15 years at Goldman Sachs building and leading its Asia-Pacific Healthcare & Life Sciences investment practice, Led investments across biotech, pharma, medtech, CROs/CDMOs and digital health over an 18-year corporate finance career, Transitioned from investor and board member to Chairman & CEO of ClinChoice

## Career timeline

- **2010s** — Managing Director at Goldman Sachs, building and leading the Asia-Pacific Healthcare & Life Sciences investing practice across biotech, pharma, medtech, CROs/CDMOs and digital health
- **2019** — Joins the board of ClinChoice (then Fountain Medical Development), with Goldman Sachs among the company's investors
- **2020** — Fountain Medical Development (FMD K&L) and affiliates rebrand as ClinChoice Inc
- **2022** — ClinChoice raises a $150M Series E funding round
- **Current** — Serves as Chairman & CEO of ClinChoice
- **2026** — Announces strategic partnership between ClinChoice and Monash University to accelerate early-phase clinical trials

## Achievements

- Over 15 years at Goldman Sachs building and leading its Asia-Pacific Healthcare & Life Sciences investment practice
- Led investments across biotech, pharma, medtech, CROs/CDMOs and digital health over an 18-year corporate finance career
- Transitioned from investor and board member to Chairman & CEO of ClinChoice
- Steered ClinChoice, a CRO that has delivered more than 3,000 studies across 15+ countries with roughly 4,000 staff
- Forged a strategic research partnership with Monash University (2026)
- Serves as Queens' Alumni Ambassador for Strategic Partnerships at the University of Cambridge

## Latest updates

- **2026-03** — ClinChoice and Monash University announced a strategic partnership to fast-track early-phase clinical trials, with Xu quoted on the company's academic-partnership mission.

## Links

- Website: https://clinchoice.com
- LinkedIn: http://www.linkedin.com/in/kevin-xu-7470897

---

Profile page: https://yespress.io/kevin-xu
Published by YesPress — https://yespress.io
Last updated: 2026-06-11